Home » Stocks » VIVE

Viveve Medical, Inc. (VIVE)

Stock Price: $3.35 USD -0.08 (-2.33%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
Pre-market: $3.34 -0.01 (-0.30%) Jan 26, 5:32 AM
Market Cap 26.88M
Revenue (ttm) 4.98M
Net Income (ttm) -35.42M
Shares Out 1.81M
EPS (ttm) -31.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $3.35
Previous Close $3.43
Change ($) -0.08
Change (%) -2.33%
Day's Open 3.41
Day's Range 3.27 - 3.50
Day's Volume 2,124,725
52-Week Range 3.17 - 18.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GuruFocus - 1 week ago

Wall Street recommends buying shares of CHF Solutions Inc (NASDAQ:CHFS) and Viveve Medical Inc (NASDAQ:VIVE), which sounds quite unexpected since these two stocks performed very poorly over th...

Other stocks mentioned: CHFS
Accesswire - 1 week ago

ENGLEWOOD, CO / ACCESSWIRE / January 14, 2021 / Viveve Medical, Inc. ("Viveve") (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced the pricing of a...

Accesswire - 1 month ago

ENGLEWOOD, CO / ACCESSWIRE /  December 17, 2020 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, announced today that it received notice f...

Seeking Alpha - 2 months ago

Viveve Medical's (VIVE) CEO Scott Durbin on Q3 2020 Results - Earnings Call Transcript

InvestorPlace - 5 months ago

Viveve Medical (VIVE) news for Tuesday includes positive results from a recent feasibility study pushing VIVE stock higher. The post Viveve Medical News: Why VIVE Stock Is Rocketing 48% Today ...

Seeking Alpha - 5 months ago

Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Inside the top-ranked stocks that have been exhibiting rising price-to-earnings ratios.

Other stocks mentioned: AVGR, BLRX, PTI, VCNX
Seeking Alpha - 8 months ago

Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 10 months ago

Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q4 2019 - Earnings Call Transcript

Seeking Alpha - 1 year ago

Viveve Medical, Inc (VIVE) CEO Scott Durbin on Q3 2019 - Earnings Call Transcript

Market Watch - 1 year ago

Shave of Viveve Medical Inc. VIVE, -5.01% sank 11% toward a record low in premarket trading Friday, after the provider of health products and women's health services filed for the sale of new ...

Seeking Alpha - 1 year ago

Viveve Medical's (VIVE) CEO Scott Durbin on Q2 2019 Results - Earnings Call Transcript

Benzinga - 1 year ago

Viveve Medical (NASDAQ: VIVE) shares are trading lower after the company said its LIBERATE-International trial in SUI patients did not not achieve its primary endpoint.

Seeking Alpha - 1 year ago

Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Viveve Medical, Inc. (VIVE) CEO Scott Durbin on Q4 2018 Results - Earnings Call Transcript

About VIVE

Viveve Medical, together with its subsidiaries, designs, develops, manufactures, and markets medical devices for the non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence. The company offers Viveve System comprises of the radiofrequency generator, reusable handpiece, and treatment tip, as well as cryogen canister and other consumable components. It markets its products through sales employees and distributors in the United States, Canada, the Asia Pacific, Europe, the Middle E... [Read more...]

Industry
Medical Devices
Founded
2005
CEO
Scott C. Durbin
Employees
55
Stock Exchange
NASDAQ
Ticker Symbol
VIVE
Full Company Profile

Financial Performance

In 2019, Viveve Medical's revenue was $6.57 million, a decrease of -64.54% compared to the previous year's $18.52 million. Losses were -$42.53 million, -14.92% less than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for Viveve Medical stock is "Strong Buy" and the 12-month stock price forecast is 22.00.

Price Target
$22.00
Analyst Consensus: Strong Buy